Genetic Technologies (ASX:GTG) completed the sale of AffinityDNA and EasyDNA to Endeavor DNA for AU$525,000, according to a Monday filing with the Australian bourse.
Endeavor has an option to purchase two of Genetic Technologies' subsidiaries that employ persons involved in conducting the acquired businesses, exercisable within four weeks after completion, the filing said.
Meanwhile, the molecular diagnostics company expects the total quantum of creditor claims to exceed that of funds held and any potential future asset recoveries. There will also likely be a shortfall to unsecured creditors. The future of the company will be decided at a meeting with creditors on Feb. 26, including either to enter into liquidation or execute a deed of company arrangement.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。